USP <800> Labeling Requirements
Medication compounding is an effective tool providers use to help meet the unique needs of patients. In fact, because of dosing requirements, allergies or rare diseases, it provides patients access to medications that would otherwise be unavailable. But medication compounding, especially sterile compounding, needs to incorporate specific standards to ensure patient safety.
That's the purpose behind USP <800>. These guidelines help to prevent sub-potent, super potent or contaminated medications and avoid exposing patients to the risk of adverse events. The USP released a final chapter effective November 1, 2023, and has issued numerous updates since then.
This article discusses those updates and the compliance steps necessary to meet USP 800 labeling requirements and ensure the safety of your staff and patients. While this guide provides a thorough overview, you should always review the official USP 800 regulations as your primary source of compliance.
Key Takeaways
- USP <800> establishes standards for safely handling hazardous drugs to protect patients, healthcare workers, and the environment.
- Proper hazardous drug labeling supports compliance during receiving, storage, transport, compounding, administration, and disposal activities.
- Healthcare organizations must identify hazardous drugs using NIOSH guidance and implement labeling systems that clearly communicate handling risks.
- Beyond Use Date (BUD) labels play a critical role in sterile and nonsterile compounding by helping prevent the use of expired compounded preparations.
- Updated USP <797> and USP <800> guidance increases the importance of precise labeling in pediatric compounding workflows where unique concentrations and shorter use windows are common.
- USP <800> permits healthcare organizations to conduct an Assessment of Risk for certain hazardous drugs, and consistent labeling helps apply those safety decisions across departments.
- Clear labeling reinforces workflow standardization, staff training, hazardous drug segregation, and safe handling protocols throughout the medication-use process.
- Durable USP <800> labels help healthcare organizations reduce exposure risks and maintain safer environments for pharmacy, nursing, environmental services, transport, and waste disposal personnel.
- Use centralized wholesaler purchase data to build accurate Assessment of Risk (AoR) lists for hazardous drug handling under USP <800>, protecting staff from unnecessary containment requirements.
Who Does USP 800 Apply To?
USP 800 applies to organizations that use HDs including:
- Pharmacies
- Hospitals
- Patient Treatment Clinics
- Physicians' Practice Facilities
- Veterinarians' Offices
The steps recommended in USP 800 promote patient safety, worker safety, and environmental protection when handling hazardous drugs. USP 800 is enforced by the FDA and other oversight agencies such as the Joint Commission.
Use these strategies to comply with the standard and protect those who administer and come into contact with hazardous drugs.
How To Comply With USP 800
Complying with USP 800 starts with identifying the type of drug you are using. For example, whether a drug is hazardous determines which regulations to follow. Further, if the drug requires compounding, you may need to implement additional controls. So first, identify the HDs you handle to ensure proper management.
Identify Hazardous Drugs (HDs)
Start by closely reading the National Institute for Occupational Safety and Health's (NIOSH) 2024 list of HDs to see which are classified as hazardous.
NIOSH defines HDs as the following:
- Carcinogenicity
- Teratogenicity or other developmental toxicity
- Reproductive toxicity
- Organ toxicity at low doses
- Genotoxicity
- Structure and toxicity profiles that mimic existing drugs determined hazardous by the above criteria
Further, this article from Pharmacy Practice News offers additional insights about identifying and handling hazardous drugs.
The Biologics Blind Spot and the Role of Risk Assessments
It is a common misconception that referencing the 2024 NIOSH list is enough to remain fully compliant. But, the official NIOSH list only captures human-use hazardous drugs approved through 2015. The wave of highly potent biologics approved since then are entirely absent from the list, yet many carry severe reproductive or organ toxicity risks.
To close this gap, pharmacies and healthcare facilities must utilize an Assessment of Risk (AoR). Instead of trying to track thousands of hypothetical drugs, organizations should look directly at their wholesaler purchase history to map out an AoR strategy based on the actual hazardous drugs and biologics they handle.
Inventory Hazardous Drugs (HDs)
Once you've identified the HDs, segregate the inventory. Typically, the hazardous drug name, its form and whether it is a tablet, capsule or liquid, should be noted. Shelf labels help communicate that vital information to your staff. In addition, precaution labels applied to the container alert workers to the hazardous drug and its potential harm.
Use Appropriate Personal Protective Equipment (PPE)
An essential USP <800> safety element is the use of appropriate PPE. Proper garbing and hand sanitation before donning gloves or other proper garbing are reinforced in this chapter.
In fact, PPE must be worn when handling HDs during receipt, storage, transport, compounding, administration, deactivation/decontamination, cleaning and disinfecting, spill control, and waste disposal. Auxiliary labels are an effective way to guide staff on the proper administration and disposal of the PPE.
Also, when entering a sterile compounding area, personnel cannot have:
- Gum or mints
- Jewelry and cosmetics
- Fingernail polish or extenders
- Eyeglasses
Further, soap containers within the area must be replaced, not refilled.
Handling and Transporting Hazardous Drugs (HDs)
When shipping HDs to locations outside your operation, consult the transport information on the safety data sheet (SDS). You must ensure that labels and accessory labeling for the HDs include storage instructions, disposal instructions, and HD category information in a format that is consistent with the carrier's policies. GHS labels are a common method used to communicate this information.
Pro Tip: How a Proper AoR Can Lower Your Containment Costs
Under USP <800>, if an organization fails to document a proper Assessment of Risk (AoR) for an unmanipulated hazardous drug, regulations force you to default to the most restrictive, expensive containment strategies available, such as heavy PPE and costly engineering controls.
But, an effective AoR can legally justify safe-handling exemptions. For example, community and hospital pharmacies frequently dispense oral contraceptives, which contain estrogen and are deemed hazardous. An AoR can explicitly note that because these pills are dispensed in their original manufacturer packaging without manipulation, heavy protective gear and negative-pressure rooms are not required.
To execute these protective boundaries safely, physical labeling is key. Utilizing high-visibility auxiliary labels that explicitly state hazardous drug instructions ensures that frontline staff instantly recognize and follow the exact safety measures outlined in your risk assessment.
Medication Compounding Labeling
Also, some HDs are formed by medication compounding. And it's the compounding area, and specifically Beyond Use Dates (BUDs) that the USP revisions impact the most.
In addition to the recommended PPE and safe handling requirements, when compounding HDs, proper labeling is a must. In fact, personnel must ensure that the labeling processes for compounded preparations do not introduce contamination into the non-HD handling areas.
Further, you should label according to state and federal regulations and include the:
- Generic or chemical names of the active ingredients
- Strength or quantity
- Pharmacy lot number
- Beyond-use date
- Any special storage requirements
Typically, organizations use pharmacy and prescription medication labels for compounding applications.
New Beyond Use Date Requirements
The new guidelines further fine tuned beyond use dates.
What Is a Beyond Use Date (BUD)?
A BUD serves to alert healthcare workers to the time/day after which a CSP or CNSP must not be used.
New Factors For Establishing BUDs
The updated guidelines introduced two primary changes to BUDs. First, compounded sterile preparations (CSPs) are now classified into Category 1 and Category 2, replacing the former microbial risk levels (low, medium, and high). These new categories are defined by the preparation conditions, the potential for microbial growth, and the permissible usage duration.
Category 3 CSPs were also introduced, outlining specific standards that facilities must maintain to assign Beyond Use Dates (BUDs). When these requirements are met, Category 3 CSPs can have extended BUDs of up to 180 days, exceeding the limits allowed for Category 2.
The revised chapter also addresses compounded nonsterile preparations (CNSPs) requiring shorter BUDs and BUDs for CNSPs that may be extended.
Compounding for Pediatric Patients
Pediatric patients often require different drug concentrations than adults, sometimes at levels not commercially available. For example, ASHP's Standardize 4 Safety initiative lists 32 medications for both adult and pediatric patients. Nearly 60% require unique pediatric strengths that often involve compounding.
Under the latest USP <797> updates, compounded stock solutions used to prepare these pediatric doses may now only be used for 12 hours, a limitation that was previously unspecified. This change underscores the need for precise labeling. Beyond Use Date labels document the end of use time and serve as a safeguard, helping to prevent clinicians from administering doses from expired stock solutions — a critical protection in high-risk pediatric care.
Pediatric compounding is just one example of how hazardous drug handling requirements can vary based on dosage form, preparation activities, and exposure risk. Under USP <800>, healthcare organizations may also conduct an Assessment of Risk to determine alternative handling practices for certain hazardous drugs.
How Labeling Supports USP <800> Assessment of Risk Programs
USP <800> permits healthcare organizations to conduct an Assessment of Risk for certain hazardous drugs and dosage forms. These risk assessments evaluate factors such as exposure potential, packaging, manipulation, and handling practices throughout the medication-use process. Clear hazardous drug labeling helps organizations apply those decisions consistently across departments by reinforcing safe handling protocols for pharmacy, nursing, transport, environmental services, and waste disposal teams. Consistent labeling also supports staff training, workflow standardization, and documentation efforts tied to USP <800> compliance programs.
USP 800 Processes Protect Your Staff
Without proper safeguards, HDs can severely impact your staff. While clinicians recognize the dangers of these drugs, they often fail to realize the exposure risks they face during daily tasks. Exposure can cause numerous issues ranging from hair loss to kidney damage and even cancer. Implementing the safeguards detailed in USP 800 will reduce those risks.
United Ad Label USP <800> Solutions
United Ad Label provides stock and custom USP <800> labels that help healthcare organizations protect their workers, patients, staff, family and visitors. Our hazardous drug labeling solutions support compliance across receiving, storage, compounding, administration, transport, and disposal workflows.
- Pharmacy and prescription medication labels for compounding applications
- Auxiliary labels for PPE guidance and administration instructions
- GHS labels for transport and hazardous drug communication
- Beyond Use Date labels for sterile and nonsterile compounding
- Shelf and precaution labels for hazardous drug segregation and inventory
Frequently Asked Questions
Why are labels important for USP <800> compliance?
Labels help healthcare workers quickly identify hazardous drugs, communicate handling requirements, reinforce storage and disposal procedures, and reduce the risk of accidental exposure or medication errors throughout the medication-use process.
What information should USP <800> labels include?
Depending on the application, USP <800> labels may include hazardous drug warnings, storage instructions, disposal requirements, Beyond Use Dates (BUDs), pharmacy lot numbers, dosage information, or handling precautions required for safe administration and transport.
Why is labeling especially important in pediatric compounding?
Pediatric patients often require unique drug concentrations that are not commercially available, making compounded medications common in pediatric care. Accurate labeling helps clinicians identify proper concentrations, monitor Beyond Use Dates, and reduce medication administration risks.
Does USP <800> require an Assessment of Risk?
USP <800> allows healthcare organizations to perform an Assessment of Risk for certain hazardous drugs and dosage forms to determine alternative containment strategies and work practices. The assessment must evaluate factors including drug type, dosage form, exposure risk, packaging, and manipulation.
Do you need to perform an Assessment of Risk (AoR) for newly approved biologics that aren't on the official NIOSH list?
Yes. The 2024 NIOSH hazardous drug list only captures human-use drugs approved through 2015. The wave of highly potent biologics approved since then are completely absent from the list, yet many carry severe reproductive or organ toxicity risks. Under USP <800>, organizations should review their actual wholesaler purchase history to identify these newer biologics and document a targeted AoR strategy.
How do labels support USP <800> compliance programs?
Hazardous drug labels help organizations identify drugs quickly, reinforce handling protocols, improve segregation practices, and communicate risks throughout receiving, storage, administration, transport, and disposal workflows.
What types of labels are commonly used for USP <800> compliance?
Healthcare organizations commonly use pharmacy labels, prescription labels, shelf labels, auxiliary labels, GHS labels, Beyond Use Date labels, transport warning labels, and hazardous drug precaution labels to support USP <800> workflows.